Literature DB >> 27160524

TARGIT-R (Retrospective): North American Experience with Intraoperative Radiation Using Low-Kilovoltage X-Rays for Breast Cancer.

Stephanie A Valente1, Rahul D Tendulkar2, Sheen Cherian2, Colin O'Rourke2, Jon M Greif3, Lisa Bailey3, Valery Uhl3, Kevin P Bethke4, Eric D Donnelly4, Ray Rudolph5, Aaron Pederson5, Thomas Summer6, S Chace Lottich7, Darrel L Ross7, Christine Laronga8, Loretta Loftus8, Andrea M Abbott8, Pond Kelemen9, Ulrich Hermanto9, Neil B Friedman10, Gauri C Bedi10, Jennifer E Joh10, William A Thompson11, Richard A Hoefer12, Jason P Wilson12, Song K Kang12, Barry Rosen13, James Ruffer13, Luis Bravo13, Alice Police14, Jamie M Escallon15, Anthony W Fyles15, David R McCready15, Gregory M Graves16, Nitin Rohatgi16, Joyce A Eaker16, Jannine Graves16, Shawna C Willey17, Eleni A Tousimis17, Brian T Collins17, Christina M Shaw18, Lee Riley19, Nimisha Deb19, Tricia Kelly19, David L Andolino19, Marc E Boisvert20, Joanne Lyons2, William Small21, Stephen R Grobmyer22.   

Abstract

BACKGROUND: Single-dose intraoperative radiotherapy (IORT) is an emerging treatment for women with early stage breast cancer. The objective of this study was to define the frequency of IORT use, patient selection, and outcomes of patients treated in North America.
METHODS: A multi-institutional retrospective registry was created, and 19 institutions using low-kilovoltage IORT for the treatment of breast cancer entered data on patients treated at their institution before July 31, 2013. Patient selection, IORT treatment details, complications, and recurrences were analyzed.
RESULTS: From 2007 to July 31, 2013, a total of 935 women were identified and treated with lumpectomy and IORT. A total of 822 patients had at least 6 months' follow-up documented and were included in the analysis. The number of IORT cases performed increased significantly over time (p < 0.001). The median patient age was 66.8 years. Most patients had disease that was <2 cm in size (90 %) and was estrogen positive (91 %); most patients had invasive ductal cancer (68 %). Of those who had a sentinel lymph node procedure performed, 89 % had negative sentinel lymph nodes. The types of IORT performed were primary IORT in 79 %, secondary IORT in 7 %, or planned boost in 14 %. Complications were low. At a median follow-up of 23.3 months, crude in-breast recurrence was 2.3 % for all patients treated.
CONCLUSIONS: IORT use for the treatment of breast cancer is significantly increasing in North America, and physicians are selecting low-risk patients for this treatment option. Low complication and local recurrence rates support IORT as a treatment option for selected women with early stage breast cancer.

Entities:  

Mesh:

Year:  2016        PMID: 27160524     DOI: 10.1245/s10434-016-5240-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Oncotype testing in patients undergoing intraoperative radiation for breast cancer.

Authors:  Kelsey E Larson; Stephanie A Valente; Chirag Shah; Rahul D Tendulkar; Sheen Cherian; Jame Abraham; Courtney Yanda; Chao Tu; Jessica Echle; Stephen R Grobmyer
Journal:  Mol Clin Oncol       Date:  2018-08-23

Review 2.  Intraoperative Radiotherapy for Breast Cancer.

Authors:  Eleanor E R Harris; William Small
Journal:  Front Oncol       Date:  2017-12-22       Impact factor: 6.244

Review 3.  Update on intraoperative radiotherapy: new challenges and issues.

Authors:  Emanuela Esposito; Michael Douek
Journal:  Ecancermedicalscience       Date:  2018-01-10

4.  Intraoperative Radiation for Breast Cancer with Intrabeam™: Factors Associated with Decreased Operative Times in Patients Having IORT for Breast Cancer.

Authors:  Stephanie A Valente; Alicia Fanning; Robyn A Stewart; Sharon Grundfest; Rahul D Tendulkar; Sheen Cherian; Chirag Shah; Chao Tu; Courtney Yanda; Diane Radford; Zahraa Al-Hilli; Stephen R Grobmyer
Journal:  Front Oncol       Date:  2017-10-09       Impact factor: 6.244

5.  Dosimetric evaluation of incorporating the revised V4.0 calibration protocol for breast intraoperative radiotherapy with the INTRABEAM system.

Authors:  Mubin Y Shaikh; Jay Burmeister; Robin Scott; Lalith K Kumaraswamy; Adrian Nalichowski; Michael C Joiner
Journal:  J Appl Clin Med Phys       Date:  2020-02-10       Impact factor: 2.102

6.  Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer.

Authors:  Lin Wang; Minmin Zhu; Yuelong Cui; Xudong Zhang; Guowen Li
Journal:  Cancer Cell Int       Date:  2020-09-11       Impact factor: 5.722

7.  Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer-better for patients, better for healthcare systems.

Authors:  Jayant Sharad Vaidya; Uma Jayant Vaidya; Michael Baum; Max Kishor Bulsara; David Joseph; Jeffrey S Tobias
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

8.  Are Patients Traveling for Intraoperative Radiation Therapy?

Authors:  Kelsey E Larson; Stephanie A Valente; Chirag Shah; Rahul D Tendulkar; Sheen Cherian; Courtney Yanda; Chao Tu; Jessica Echle; Stephen R Grobmyer
Journal:  Int J Breast Cancer       Date:  2017-10-09

9.  Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT).

Authors:  Melvin J Silverstein; Melinda S Epstein; Peter Chen; Kevin Lin; Sadia Khan; Lincoln Snyder; Colleen Coleman; Lisa Guerra; Farideh Dehkordi-Vakil; Brian Kim
Journal:  Ann Surg Oncol       Date:  2022-01-22       Impact factor: 4.339

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.